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2005;352:1425–35.ReplyIs Myopathy the
Achilles’ Heel of Statins?
Differences Between the New
Cholesterol Treatment Guidelines
and Everyday Clinical PracticeThe American College of Cardiology Foundation/American Heart
Association (ACCF/AHA) welcomes letters to inform its ongoing
work and encourages such correspondence about its guidelines.
Because the ACCF/AHA guideline development process is
rigorous and involves several layers of review by the writing com-
mittee, external peer reviewers, and participating organizations in
the document, it cannot respond to each issue raised after a
guideline has been published. The information, however, is for-
warded to the writing committee chair and oversight task forcefor review. If any issue is deemed by the ACCF/AHA to affect
patient safety, it will be considered immediately. Otherwise, the
information will be considered during the next update or revision
of the guideline.The American College of Cardiology
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Thickness and Cardiovascular
Disease Risk Prediction
The 2013 American College of Cardiology and American Heart
Association guideline on the assessment of cardiovascular risk
gave a class III recommendation for carotid intima-media thick-
ness (IMT) testing (1). This assessment was based on an inac-
curate description of the clinical use of carotid IMT testing by
focusing only on the common carotid artery (CCA). The Amer-
ican Society of Echocardiography consensus statement (2) and
others have speciﬁed that carotid ultrasound for cardiovascular
disease risk prediction should be based on a thorough scan of the
carotid arteries for the presence of plaques, followed by mea-
surement of CCA IMT. This is because the presence and extent
of carotid plaque, which occurs predominantly in the carotid
bifurcation and internal carotid artery, rather than the CCA, are
independent predictors of future cardiovascular disease events
and in observational studies have performed better than CCA IMT
alone (3). The consensus statement, which has been widely adop-
ted, speciﬁcally stipulates that measuring CCA IMT without
considering plaque presence is not sufﬁcient; however, the evidence
that provided the working group with the “strongest evidence” for
its class III recommendation was a meta-analysis based solely on
CCA IMT (4).
The working group raised important concerns about stan-
dardization and measurement issues, but the clinical use of this
test has been standardized for more than 5 years (2) and has
published appropriate use criteria (5), and its reproducibility
is excellent, even in inexperienced hands. We believe that a
class IIb recommendation would be more appropriate, on the
basis of the test characteristics of carotid IMT plus plaque
scanning.
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